Brought to you by 
Baxter gets exclusive rights to Merrimack's late-stage pancreatic cancer candidate MM398
20 Sep 2018
Executive Summary
Merrimack Pharmaceuticals Inc. (oncology drug development) granted Baxter International Inc. exclusive worldwide rights to sell its MM398 for patients with pancreatic cancer who have already been treated with gemcitabine. The deal excludes the US, where Merrimack retains rights, and Taiwan, where PharmaEngine already holds a license.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter gets exclusive rights to Merrimack's late-stage pancreatic cancer candidate MM398
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice